Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
Obesity continues to exist around the world despite the risk to health and death from illness and disease.
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.
Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.
A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.
Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.
Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis
1.
tobacco use, the severity of their symptoms, and their desire to give up smoking among cancer survivors.
2.
Poor agreement between diagnostic tests for breast cancer-related lymphedema
3.
High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment
4.
Error on the MGUS-Autoimmune Disease Association.
5.
Cancer After Weight Loss; How Older Adults Use the Healthcare System.
1.
AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology
2.
The latest Hematocrit: An Overview of Red Blood Cell Health
3.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
4.
Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence
5.
An Analytical and Statistical Journey through Genomic Revolution, Novel Therapeutics, and Future Horizons in Lymphoma 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge